Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.

ABSTRACT:

Background

Sodium-glucose cotransporter-2 inhibitors promote glycosuria, resulting in possible effects on calcium, phosphate, and vitamin D homeostasis. Canagliflozin is associated with decreased bone mineral density and a potential increased risk for fracture.

Objective

To estimate risk for nonvertebral fracture among new users of canagliflozin compared with a glucagon-like peptide-1 (GLP-1) agonist.

Design

Population-based new-user cohort study.

Setting

Two U.S. commercial health care databases providing data on more than 70 million patients from March 2013 to October 2015.

Patients

Persons with type 2 diabetes who initiated use of canagliflozin were propensity score-matched in a 1:1 ratio to those initiating use of a GLP-1 agonist.

Measurements

SUBMITTER: Fralick M 

PROVIDER: S-EPMC6602870 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature